DNTH
Time to buy DNTH?$93.01
+$2.15 (2.37%)
2 Days. Real Options Skills.
Join options trader Ben Sturgill as he reveals his most reliable options strategies - live. Seats are limited.
Save your seatTrader's Perspective
DNTH ran from roughly $49 in mid-February to a fresh high near $96.50 in late May after its early Phase 3 CAPTIVATE GO decision, a $719 million financing, and continued pipeline updates kept biotech traders engaged.
A failure to hold $88 could see a retrace toward the $80 to $82 zone. Any softer tone on clinical timelines or renewed concern over dilution from the March offering and warrant overhang would accelerate the downside.
If DNTH holds the $88 to $90 area, a move back toward $96.50 to $100 is on the table. Resistance at $96.50 is the first hurdle, and continued interest around claseprubart and June healthcare conference commentary could help.
Analyst Ratings
Dianthus Therapeutics Inc. Earnings
We don't currently have information about Dianthus Therapeutics Inc.'s earnings.